Skip to main content
SpringerLink
Log in

Personalized Medicine for Cancer

  • Chapter
General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Part of the book series: Methods of Cancer Diagnosis, Therapy, and Prognosis ((HAYAT,volume 2))

  • 1163 Accesses

Personalized medicine is a model of the way medicine will evolve through the use of specific treatments and therapies best suited to an individual's genotype and is driven by patient demand for safer and more effective medicines and therapies. This chapter focuses on the role of personalized medicine in cancer and explores its use in current clinical practice, its likely application in the future and the challenges which need to be overcome in order to achieve this goal. Economic, social, and ethical considerations relating to personalized medicine are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderlik, M.R., and Rothstein, M.A. 2001. Privacy and confidentiality of genetic information: what rules for the new science? Annu. Rev. Genom. Hum. Genet. 2: 401–433

    Article  CAS  Google Scholar 

  • Baccarani, M., Saglio, G., Goldman, J.M., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J.F., Cervantes, F., Cortes, J., Deininger, M.W., Gratwohl, A., Guihot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R.A., Niederwieser, D., Silver, R.T., and Hehlmann, R. 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an exert panel on behalf of the European Leukemia Net. Blood 108: 1809–1820

    Article  PubMed  CAS  Google Scholar 

  • Baylin, S.B., Esteller, M., Rountree, M.R., Bachman, K.E., Schuebel, K., and Herman, J.G. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10: 687–692

    Article  PubMed  CAS  Google Scholar 

  • Bosanquet, N., and Sikora, K. 2006. The Economics of Cancer Care. Cambridge University Press, Cambridge

    Google Scholar 

  • Branford, S., Rudzki, Z., Parkinson, I., Grigg, A., Taylor, K., Seymour, J.F., Durrant, S., Browett, P., Schwarer, A.P., Arthur, C., Catalano, J., Leahy, M.F., Filshie, R., Bradstock, K., Hermann, R., Joske, D., Lynch, K., and Hughes, T. 2004. Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104: 2926–2932

    Article  PubMed  CAS  Google Scholar 

  • Caldas, C., and Aparicio, S.A. 2002. The molecular outlook. Nature 415: 484–485

    Article  PubMed  CAS  Google Scholar 

  • Capdeville, R., Buchdunger, E., Zimmerman, J., and Matter, A. 2002. Glivec (ST571,imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1: 493–502

    Article  CAS  Google Scholar 

  • Cohen, M.H., Johnson, J.R., Chen, Y.F., Sridhara, R., and Pazdur, R. 2005. FDA approval summary: erlotinib (Tarceva) tablets. Oncologist 10: 461–466

    Article  PubMed  CAS  Google Scholar 

  • Collins, I., and Workman, P. 2006. New approaches to molecular cancer therapeutics. Nature Chem. Bio. 2: 689–700

    Article  CAS  Google Scholar 

  • Dietel, M., and Sers, C. 2006. Personalized medicine and development of targeted therapies: the up-coming challenge for diagnostic molecular pathology. A review. Virchows Arch. 448: 744–755

    Article  PubMed  Google Scholar 

  • Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, V.L. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031–1037

    Article  PubMed  CAS  Google Scholar 

  • Eng, C., and Mulligan, L.M. 1997. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 related sporadic tumors and Hirschsprung disease. Hum. Mutat. 9: 97–109

    Article  PubMed  CAS  Google Scholar 

  • Futreal, P.A. 2004. A consensus of human cancer genes. Nature Rev. Cancer. 4: 177–183

    Article  CAS  Google Scholar 

  • Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., Bloomfield, C.D., and Lander, E.S. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537

    Article  PubMed  CAS  Google Scholar 

  • Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., and Stratton, M.R. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158

    Article  PubMed  CAS  Google Scholar 

  • Hadj Tahar, A. 2004. Bevacizumab for advanced colorectal cancer. Is. Emerg. Hlth. Technol. 63: 1–4

    Google Scholar 

  • Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Siberman, S., Dimitrijevic, S., and Fletcher, J.A. 2003. Kinase mutations and imatinib response in patients with gastrointestinal stromal tumors. J. Clin. Oncol. 21: 4342–4349

    Article  PubMed  CAS  Google Scholar 

  • Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., and Kitamura, Y. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580

    Article  PubMed  CAS  Google Scholar 

  • Jones, P.A., and Baylin, S.B. 2002. The fundamental role of epigenetic events in cancer. Nature Rev. Gene. 3: 415–428

    CAS  Google Scholar 

  • Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F.J., Rosenzweig, A., Salomon, R.N., Van Etten, R.A., Alroy, J., Durand, J.B., and Force, T. 2006. CardiotoxiCity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12: 908–916

    Article  PubMed  CAS  Google Scholar 

  • King, I.B., Satia-Abouta, J., Thornquist, M.D., Bigler, J., Patterson, R.E., Kristal, A.R., Shattuck, A.L., Potter, J.D., and White, E. 2002. Buccal cell DNA yield, quality, and collection costs: comparison of methods for large scale studies. Cancer Epidemiol. Biomarkers Prev. 11: 1130–1133

    PubMed  Google Scholar 

  • Kolch, W., Mischak, H., and Pitt, A.R. 2005. The molecular make-up of a tumor: proteomics in cancer research. Clin. Science 108: 369–383

    Article  CAS  Google Scholar 

  • Kubota, T. 2006. Gastrointestinal stromal tumor (GIST) and imatinib. Intern. J. Clin. Oncol. 11: 184–189

    Article  CAS  Google Scholar 

  • Kurhanewiez, J., Swanson, M.G., Nelson, S.J., and Vigeron, D.B. 2002. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imag. 16: 451–463

    Article  Google Scholar 

  • Mauro, M.J. and Deininger, M.W. 2006. Chronic myeloid leukemia in 2006: a perspective. Haematologica 91: 152

    PubMed  CAS  Google Scholar 

  • Morris, S., and Carey, L. 2006. Trastuzumab and beyond: new possibilities for the treatment of HER2- positive breast cancer. Oncology 20: 1763–1771

    PubMed  Google Scholar 

  • Murphy, P.S., Dzik-Jurasz, A., Baustert, I., Leach, M.O., and Rowland, I.J. 2000. Choline signal correlates with vascular permeability in human gliomas. Proc. Intern, Soc. Magn. Reson. Med. 8: 393

    Google Scholar 

  • Murphy, P.S., Viviers, L., Abson, C., Rowland, I.J., Brada, M. and Leach, M. 2004. Monitoring temozolamide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Brit. J. Cancer 90: 781–786

    Article  PubMed  CAS  Google Scholar 

  • Nakamura, T., Ishizaka, Y., Nagao, M., Hara, M., and Ishikawa, T. 1994. Expression of the RET proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J. Patho. 172: 255–260

    Article  CAS  Google Scholar 

  • Robertson, J.A. 2001. Consent and privacy in pharmacogenetic testing. Nat. Genet. 28: 207–209

    Article  PubMed  CAS  Google Scholar 

  • Robertson, J.A., Brody, B., Buchanan, A., Kahn, J., and McPherson, E. 2002. Pharmacogenetic challenges for the health care system. Health Aff. (Millwood) 21: 155–167

    Article  Google Scholar 

  • Samoylova, T.I., Morrison, N.E., Globa, L.P., and Cox, N.R. 2006. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anti-cancer Agents Med. Chem. 6: 9–17

    Article  CAS  Google Scholar 

  • Schwarz, A.J., Maisey, N.R., Collins, D.J., Cunningham, D., Huddart, R., and Leach, M.O. 2002. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and erm cell tumors. Brit. J. Radio. 75: 959–966

    CAS  Google Scholar 

  • Sibtain, N.A., Howe, F.A., and Saunders, D.E. 2007. The clinicalvaue of proton magnetic resonance spectroscopy in adult brain tumors. Clin. Radio. 62: 109–119

    Article  CAS  Google Scholar 

  • Sihto, H., Sarlomo-Rikala, M., Tynninen, O., Tanner, M., Andersson, L.C., Franssila, K., Nupponen, N.N., and Joensuu, H. 2005. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J. Clin. Oncol. 23: 49–57

    Article  PubMed  CAS  Google Scholar 

  • Sikora, K. 2007. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv. Cancer Res. 96: 345–369

    Article  PubMed  CAS  Google Scholar 

  • Silver, M., Talpaz, M., Sawyers, C.L., Druker, B.J., Hochhaus, A., and Schiffer, C.A. 2004. Four years follow up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [Abstract number 23]. Blood 104: 10a

    Google Scholar 

  • Takahashi, M. 1988. Cloning and expression of the RET oncogene encoding a receptor tyrosine kinase with two potential transmembrane domains. Oncogene 3: 571–578

    PubMed  CAS  Google Scholar 

  • Talpaz, M., Goldman, J.M., Sawyers, C.L., Hochhaus, A., Silver, R.T., and Douglas-Smith, B.D. 2003. High dose imatitinib (STI571,Gleevec) provides durable long-term outcomes for patiens (pts) with chronic myeloid leukemia (CML), in accelerated phase (AP) or myeloid blast crisis (BC): follow up of the phase II studies [Abstract]. Blood 102: 905a–906a

    Google Scholar 

  • Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brian, S.G.

    Google Scholar 

  • Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.T., Huang, F., Decillis, A.P., and Sawyers, C.L. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354: 2531–2541

    Article  PubMed  Google Scholar 

  • Van't Veer, L.J., Dai, H., van de Vijer, M.J., He, Y.D., Hart, A.A., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., and Friend, S.H. 2002. Gene expression profiling predicts clinical outcome in breast cancer. Nature 415: 530–536

    Article  Google Scholar 

  • Watters, J.W., and McLeod, H.L. 2003. Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta 1603: 99–111

    PubMed  CAS  Google Scholar 

  • Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., and Griffin, J.D. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Brit. J. Cancer 94: 1765–1769

    Article  PubMed  CAS  Google Scholar 

  • Wolf, W., Waluch, V., and Presant, C.A. 1998. Non-invasive 19F-MRS of 5-fluorouracil in pharmacokinetics and pharmacodynamics. NMR Biomed. 11: 380–387

    Article  PubMed  CAS  Google Scholar 

  • Workman, P., Aboagye, E.O., Chung, Y.-L., Griffiths, J.R., Hart, R., Leach, M., Maxwell, R.J., McSheehy, P.M.J., Price, P., and Zweit, J. 2006. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis testing clinical trials of innovative therapies. J. Nat. Cancer Instit. 98: 580–598

    Article  CAS  Google Scholar 

  • Wulfkuhle, J.D., Auino, J.A., Calvert, V.S., Fishman, D.A., Coukos, G., Liotta, L.A., and Petricoin, E.F. 2003. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3: 2085–2090

    Article  PubMed  CAS  Google Scholar 

  • Yeoh, E.J., Ross, M.E., Shurtleff, S.A., Williams, W.K., Patel, D., Mahfouz, R., Behm, F.G., Raimondi, S.C., Relling, M.V., Patel, A., Cheng, C., Campana, D., Wilkins, D., Zhou, X., Li, J., Lui, H., Pui, C.H., Evans, W.E., Naeve, C., Wong, L., Wong, L., and Downing, J.R. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133–143

    Article  PubMed  CAS  Google Scholar 

  • Yong, W.P., Innocenti, F., and Ratain, M.J. 2006. The role of pharmacogenetics in cancer therapy. Br. J. Clin. Pharmacol. 62: 35–46

    Article  PubMed  CAS  Google Scholar 

  • Zbuk, K.M., and Eng, C. 2007. Cancer phenomics: RET and PTEN as illustrative models. Nature Rev. Cancer 7: 35–45

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Oxford, Harris Manchester College, Manchester Road, Oxford OX1 3 TD, UK

    Sarah J. Welsh

  2. Department of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe, Blvd., FC6. 3044, Unit 422, Houston, TX, 77030

    Garth Powis

Authors
  1. Sarah J. Welsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garth Powis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Garth Powis .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Kean University, Union, NJ, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media B.V

About this chapter

Cite this chapter

Welsh, S.J., Powis, G. (2008). Personalized Medicine for Cancer. In: Hayat, M.A. (eds) General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Methods of Cancer Diagnosis, Therapy, and Prognosis, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8442-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-8442-3_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-8441-6

  • Online ISBN: 978-1-4020-8442-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation